Skip to main
MLYS
MLYS logo

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics Inc. has demonstrated positive advancements in its clinical program for lorundrostat, reporting a significant placebo-adjusted blood pressure reduction of 9.1 mmHg at six weeks and 11.7 mmHg at twelve weeks in uncontrolled and resistant hypertension patients. The medication's safety profile is notably favorable, with a hyperkalemia rate of only 1.1% at the optimized dosing, indicating its potential for daily use among patients despite existing antihypertensive therapies. Additionally, the data suggests a robust efficacy of 8-12 mmHg blood pressure improvement, which positions lorundrostat as a viable treatment option and enhances the overall outlook for Mineralys Therapeutics in the biopharmaceutical market.

Bears say

Mineralys Therapeutics Inc. reported a significant net loss of $48.9 million for the fourth quarter of 2024 and a total net loss of $177.8 million for the entire year, reflecting ongoing financial challenges. The company faces substantial risks, including the possibility that its developmental candidate, lorundrostat, may not meet commercial revenue estimates, which could be affected by market conditions and pricing strategies. Additionally, there are concerns regarding the company’s ability to secure sufficient capital to fund operations and advance its program development and commercialization efforts.

MLYS has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 8 analysts, MLYS has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.